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Background
Coronavirus Disease 2019 is a pandemic that is straining healthcare resources, mainly hospital beds. Multiple risk factors of disease progression requiring hospitalization have been
identified, but medical decision-making remains complex.

Objective
To characterize a large cohort of patients hospitalized with COVID-19, their outcomes,
develop and validate a statistical model that allows individualized prediction of future hospitalization risk for a patient newly diagnosed with COVID-19.

Published: August 11, 2020
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is available here:
https://doi.org/10.1371/journal.pone.0237419
Copyright: © 2020 Jehi et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Data used for the
generation of this risk prediction model includes
human research participant data that are sensitive
and cannot be publicly shared due to legal and

Design
Retrospective cohort study of patients with COVID-19 applying a least absolute shrinkage
and selection operator (LASSO) logistic regression algorithm to retain the most predictive
features for hospitalization risk, followed by validation in a temporally distinct patient cohort.
The final model was displayed as a nomogram and programmed into an online risk
calculator.

Setting
One healthcare system in Ohio and Florida.

Participants
All patients infected with SARS-CoV-2 between March 8, 2020 and June 5, 2020. Those
tested before May 1 were included in the development cohort, while those tested May 1 and
later comprised the validation cohort.
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Hospitalization risk prediction and outcomes in COVID-19

Measurements
Demographic, clinical, social influencers of health, exposure risk, medical co-morbidities,
vaccination history, presenting symptoms, medications, and laboratory values were collected on all patients, and considered in our model development.

Results
4,536 patients tested positive for SARS-CoV-2 during the study period. Of those, 958
(21.1%) required hospitalization. By day 3 of hospitalization, 24% of patients were transferred to the intensive care unit, and around half of the remaining patients were discharged
home. Ten patients died. Hospitalization risk was increased with older age, black race, male
sex, former smoking history, diabetes, hypertension, chronic lung disease, poor socioeconomic status, shortness of breath, diarrhea, and certain medications (NSAIDs, immunosuppressive treatment). Hospitalization risk was reduced with prior flu vaccination. Model
discrimination was excellent with an area under the curve of 0.900 (95% confidence interval
of 0.886–0.914) in the development cohort, and 0.813 (0.786, 0.839) in the validation cohort.
The scaled Brier score was 42.6% (95% CI 37.8%, 47.4%) in the development cohort and
25.6% (19.9%, 31.3%) in the validation cohort. Calibration was very good. The online risk
calculator is freely available and found at https://riskcalc.org/COVID19Hospitalization/.

Limitation
Retrospective cohort design.

Conclusion
Our study crystallizes published risk factors of COVID-19 progression, but also provides
new data on the role of social influencers of health, race, and influenza vaccination. In a context of a pandemic and limited healthcare resources, individualized outcome prediction
through this nomogram or online risk calculator can facilitate complex medical decisionmaking.

Introduction
Based on the latest estimates from the Centers for Disease Control (week ending in June 6,
2020), hospitalization rates in the United States due to Coronavirus disease of 2019 (COVID19) range from 5.6/100,000 population in patients 4 years or younger and up to 273.8/100,000
population in those 65 years or older, posing a significant capacity challenge to the healthcare
system. Strategies to address this challenge have focused on imposing social distancing to
reduce viral transmission and increasing hospital bed capacity by drastically reducing usual
occupancy, eliminating elective surgical procedures, and creating makeshift surge hospitals
[1]. Social distancing practices have indeed helped in curbing the acute need for hospital beds–
at least momentarily- but the long-term healthcare capacity requirements remain unclear as
strategies for lifting restrictions and resuming normal activities are in flux. Improving our
understanding of the clinical outcomes of patients infected with COVID-19 is therefore paramount. In addition, we need predictive algorithms that identify the COVID-19 patients at
highest risk of progressing to severe disease to develop alternative approaches to safely manage
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them. These predictive algorithms could also be used at a population level to guide social distancing and other risk limiting strategies in a focused fashion, rather than the blanket
approaches of shelter-in-place for society.
Older age [2–3], smoking [4], and medical co-morbidities such as diabetes, hypertension,
cardiovascular disease, chronic kidney disease, chronic lung disease [5], and cancer [5–6]
have been correlated with disease worsening in patients who are already hospitalized with
COVID-19. It is unclear how these comorbidities, or other patient characteristics, factor into
clinical worsening that leads to hospitalization. Translating their significance at an individual
patient care level when faced with a decision to hospitalize patients presenting with symptoms of COVID-19 is even more elusive. The end result is patients being told to go home
from the emergency room only to return much more ill and be admitted days later, or
patients hospitalized for observation for several days without any significant clinical
deterioration.
We present the clinical characteristics and outcomes of patients with COVID-19, including
a subset who were hospitalized. We also develop and validate a statistical model that can assist
with individualized prediction of hospitalization risk for a patient with COVID-19. This
model allows us to generate a visual statistical tool (a nomogram) that can consider numerous
variables to predict an outcome of interest for an individual patient [7].

Methods
Patient selection
We included all patients, regardless of age, who had positive COVID-19 testing at Cleveland
Clinic between March 8, 2020 and June 5, 2020. The study cohort included all Covid positive
patients, whether they were hospitalized or not, from across the Cleveland clinic health system
which includes >220 outpatient locations and18 hospitals in Ohio and Florida. As testing
demand increased, we adapted our organizational policies and protocols to reconcile demand
with patient and caregiver safety. Prior to March 18, any primary care physician could order a
COVID-19 test. After that date, testing resources were streamlined through a “COVID-19
Hotline” which followed recommendations from the Centers for Disease Control (recommending to focus on high risk patients as defined by any of the following: Age older than 60
years old or less than 36 months old; on immune therapy; having comorbidities of cancer,
end-stage renal disease, diabetes, hypertension, coronary artery disease, heart failure with
reduced ejection fraction, lung disease, HIV/AIDS, solid organ transplant; contact with known
COVID 19 patients; physician discretion was still allowed).

Cleveland clinic COVID-19 registry
Demographics, co-morbidities, travel and COVID-19 exposure history, medications, presenting symptoms, socioeconomic measures, treatment, disease progression, and outcomes were
collected. Registry variables were chosen to reflect available literature on COVID-19 disease
characterization, progression, and proposed treatments, including medications thought to
have benefits through drug-repurposing studies [8]. Capture of detailed research data was
facilitated by the creation of standardized clinical templates that were implemented across the
healthcare system as patients were seeking care for COVID-19-related concerns. Outcome
capture was facilitated by a home monitoring program whereby patients who tested positive
were called daily for 14 days after–test result to monitor their disease progression.
Data were extracted via previously validated automated feeds [9] from our electronic health
record (Epic, Epic Systems Corporation) and manually by a study team trained on uniform
sources for the study variables. The COVID-19 Research Registry team includes a “Reviewer”
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group and a “Quality Assurance” group. The reviewers were responsible for manually abstracting and entering a subset of variables (signs and symptoms upon presentation) that cannot be
automatically extracted from the electronic health record, and for verifying high-priority variables (co-morbidities) that have been automatically pulled into the database from the electronic health record. The Quality Assurance group provided an independent second layer of
review. Study data were collected and managed using REDCap electronic data capture tools
hosted at Cleveland Clinic [10–11]. REDCap (Research Electronic Data Capture) is a secure,
web-based software platform designed to support data capture for research studies, providing
1) an intuitive interface for validated data capture; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to
common statistical packages; and 4) procedures for data integration and interoperability with
external sources.
This research was approved by the Cleveland Clinic Institutional Review Board (IRB# 20–
283). Consent was waived by IRB.

COVID-19 testing protocols
Nasopharyngeal and oropharyngeal swab specimens were both collected in all patients and
pooled for testing by trained medical personnel. Given previous beliefs that co-infection with
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory viruses
is rare [12–13], a reflex testing algorithm was implemented to conserve resources. All patient
specimens were first tested for the presence of influenza A/B and respiratory syncytial virus
(RSV), and only those negative for influenza and RSV were subsequently tested for SARS-CoV-2.
Infection with SARS-CoV-2 was confirmed by laboratory testing using the Centers for Disease Control and Prevention (CDC) reverse transcription polymerase chain reaction
(RT-PCR) SARS-CoV-2 assay that was validated in the Cleveland Clinic Robert J. Tomsich
Pathology and Laboratory Medicine Institute. This assay uses Roche Magnapure extraction
and ABI 7500 DX PCR instruments. Between March 8 and 13, the tests were sent out to LabCorp, Burlington, North Carolina. All testing was authorized by the Food and Drug Administration under an Emergency Use Authorization (EUA), and in accordance with the guidelines
established by the CDC.

Statistical methods
Baseline data are presented as median [interquartile range [IQR]) and number (%)]. Continuous variables were compared using the Mann-Whitney U test, and categorical variables were
compared using the Chi-square test. The outcome of interest was hospitalization anytime
within three days of a positive COVID test. The model was built using a development cohort
(patients with COVID positive test resulted before May 1, 2020), and subsequently tested in a
validation cohort (patients with COVID positive test resulted between May 1 and June 5,
2020). This allowed us to test the model’s validity over time. A full multivariable logistic model
was initially constructed to predict hospital admission with COVID-19 based on demographic
variables, comorbidities, immunization history, symptoms, travel history, lab variables, and
medications that were identified pre-admission. For modeling purposes, methods of missing
value imputation for labs variables were compared using median values and using values from
multivariate imputation by chained equations (MICE) via the R package mice. Restricted
cubic splines with 3 knots were applied to continuous variables to relax the linearity assumption. A least absolute shrinkage and selection operator (LASSO) logistic regression algorithm
was performed to retain the most predictive features. A 10-fold cross validation method was
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applied to find the regularization parameter lambda which gave the minimum mean cross-validated concordance index. Predictors with nonzero coefficients in the LASSO regression
model were chosen for calculating predicted risk. The final model was internally validated by
assessing the discrimination and calibration with 1000 bootstrap resamples. Discrimination
was measured with the concordance index [14]. Calibration was assessed visually by plotting
the nomogram predicted probabilities against the observed event proportions over a series of
equally spaced values within the range of the predicted probabilities. The closer the calibration
curve lies along the 45˚ line, the better the calibration. A scaled Brier score, called the index of
predictive accuracy (IPA) [15], was also calculated, as this has some advantages over the more
popular concordance index. The IPA ranges from -1 to 1, where a value of 0 indicates a useless
model, and negative values imply a harmful model. We adhered to the TRIPOD checklist for
reporting the prediction model [16].
We calculated sensitivity, specificity, positive addictive value, negative predictive value at
different cutoffs of predicted risk. We used R, version 3.5.0 (R Project for Statistical Computing) [17], with tidyverse [18], mice [19], caret [20], and risk Regression [21] packages for all
analyses. Statistical tests were 2-sided and used a significance threshold of P < .05. We
included all COVID positive patients during the study period in this model development and
validation to optimize model performance: no specific sample size calculations were
performed.

Sensitivity analyses
An outcome of “hospitalized versus not” allows us to predict the likelihood that the patient is
actually getting admitted to the hospital. This decision, however, is influenced by multiple
“non-medical” factors including bed availability, regulatory systems, and individual physician
preferences. To test the applicability of our model towards a determination of whether a
patient should have been admitted or not, we subdivided patients included in our validation
cohort and development cohorts into 4 categories: A- hospitalized and not sent home within
24 hours; B- sent home (not initially hospitalized) but ultimately hospitalized within 1 week of
being sent home; C- not hospitalized at all; D- hospitalized but sent home within 24 hours. In
this construct, categories A and C represent patients who were “correctly managed”, at categories B and D represent those who were “incorrectly managed”. We then tested the discrimination of our model in each one of those categories separately.
No model recalibration was done.

Results
Patient characteristics and outcomes
4,536 patients tested positive during the study period, including 2,852 patient in the development cohort (DC) of whom 582 (20.4%) were hospitalized, and 1,684 patients in the validation
cohort (VC) of whom 376 (22.3%) were hospitalized. Table 1 provides demographic, exposure,
clinical, laboratory, social characteristics, and medication history of COVID-19 patients who
were hospitalized versus those who completed their treatment on an outpatient basis in both
the DC and VC. At the time of hospital admission, 260 patients were known to have COVID19, while the results of the (RT-PCR) SARS-CoV-2 nasopharyngeal assay were still pending on
698. Six hundred and sixty five were admitted from the emergency room, 32 were transferred
from other hospitals, and 261 were directly admitted from the outpatient areas. Overall outcomes illustrated in Fig 1 show the cumulative incidence of hospital discharge, transfer to
intensive care unit, and death in our hospitalized cohort.
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Table 1. Detailed descriptive statistics of demographic, exposure, clinical, laboratory, social characteristics, and medication history of COVID-19 positive patients
who were hospitalized versus not. Statistically significant variables (p-value<0.05) are bolded. The development data is before 05/01 and the validation data is between
05/01 and 06/05. The percentages presented are per row.
Development Cohort
Not hospitalized
N

Validation Cohort

hospitalized

2270

p-value
582

Not hospitalized

hospitalized

1308

376

8 (53.3)

7 (46.7)
199 (32.0)

p-value

Demographics:
Race (%)

<0.001
Asian

27 (77.1)

8 (22.9)

<0.001

Black

498 (70.0)

213 (30.0)

422 (68.0)

Other

362 (93.5)

25 (6.5)

239 (90.5)

25 (9.5)

White

1383 (80.5)

336 (19.5)

639 (81.5)

145 (18.5)

1049 (76.5)

323 (23.5)

556 (75.3)

182 (24.7)

Male (%)
Ethnicity (%)

<0.001

0.049

<0.001

<0.001

Hispanic

326 (93.9)

21 (6.1)

99 (84.6)

18 (15.4)

Non-Hispanic

1677 (75.2)

553 (24.8)

925 (72.8)

345 (27.2)

Unknown

267 (97.1)

8 (2.9)

284 (95.6)

13 (4.4)

Current Smoker

136 (78.6)

37 (21.4)

111 (71.2)

45 (28.8)

Smoking (%)

<0.001

<0.001

Former Smoker

642 (74.4)

221 (25.6)

301 (70.2)

128 (29.8)

No

1182 (79.6)

302 (20.4)

613 (78.8)

165 (21.2)

Unknown

310 (93.4)

22 (6.6)

50.57 [35.75, 64.40]

64.37 [54.83, 76.58]

Age (median [IQR]) Missing: 0.5%

283 (88.2)

38 (11.8)

<0.001

45.57 [30.49, 65.93]

64.94 [52.45, 76.78]

<0.001

Exposure history:
Exposed to COVID-19? YES (%)

1725 (81.6)

390 (18.4)

<0.001

732 (78.3)

203 (21.7)

0.535

Family member with COVID-19? YES (%)

1565 (80.3)

383 (19.7)

0.161

557 (75.0)

186 (25.0)

0.021
0.781

Presenting symptoms:
Cough? Yes (%)

662 (77.3)

194 (22.7)

Fever? Yes (%)

1534 (79.2)

403 (20.8)

0.472

505 (77.3)

148 (22.7)

0.838

Fatigue? Yes (%)

1479 (76.8)

446 (23.2)

<0.001

531 (73.9)

188 (26.1)

0.001
0.114

Sputum production? Yes (%)

1889 (79.8)

478 (20.2)

1042 (78.8)

280 (21.2)

0.576

458 (75.5)

149 (24.5)

Flu-like symptoms? Yes (%)

1711 (80.0)

429 (20.0)

0.439

0.365

659 (78.9)

176 (21.1)

0.245

Shortness of breath? Yes (%)

1098 (72.3)

421 (27.7)

<0.001

379 (66.5)

191 (33.5)

<0.001

Diarrhea? Yes (%)

995 (78.6)

271 (21.4)

0.256

370 (74.0)

130 (26.0)

0.022

Loss of appetite? Yes (%)

1222 (77.2)

360 (22.8)

0.001

464 (73.0)

172 (27.0)

<0.001

Vomiting? Yes (%)

711 (81.7)

159 (18.3)

0.069

282 (75.2)

93 (24.8)

0.217

BMI (median [IQR]) Missing: 52.7%

29.27 [25.73, 33.98]

30.30 [26.29, 35.46]

0.03

30.05 [25.71, 35.18]

29.02 [24.80, 34.95]

0.15

COPD/emphysema? Yes (%)

102 (58.0)

74 (42.0)

<0.001

43 (50.6)

42 (49.4)

<0.001

Asthma? Yes (%)

264 (67.9)

125 (32.1)

<0.001

198 (75.6)

64 (24.4)

0.419

Diabetes? Yes %)

358 (60.3)

236 (39.7)

<0.001

193 (57.1)

145 (42.9)

<0.001

Co-morbidities:

Hypertension? Yes (%)

800 (65.6)

419 (34.4)

<0.001

462 (64.7)

252 (35.3)

<0.001

Coronary artery disease? Yes (%)

172 (57.3)

128 (42.7)

<0.001

125 (61.3)

79 (38.7)

<0.001

Heart failure? Yes (%)

122 (52.4)

111 (47.6)

<0.001

80 (51.6)

75 (48.4)

<0.001

Cancer? Yes (%)

230 (66.7)

115 (33.3)

<0.001

124 (72.1)

48 (27.9)

0.079

<0.001

2 (22.2)

7 (77.8)

<0.001

Transplant history? Yes (%)

10 (41.7)

14 (58.3)

Multiple sclerosis? Yes (%)

23 (76.7)

7 (23.3)

0.863

11 (68.8)

5 (31.2)

0.576

Connective tissue disease? Yes (%)

165 (69.3)

73 (30.7)

<0.001

47 (74.6)

16 (25.4)

0.658

Inflammatory Bowel Disease? Yes (%)

80 (72.1)

31 (27.9)

0.059

27 (75.0)

9 (25.0)

0.852

Immunosuppressive disease? Yes (%)

164 (59.0)

114 (41.0)

<0.001

125 (59.8)

84 (40.2)

<0.001
(Continued )
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Table 1. (Continued)
Development Cohort
Not hospitalized
N

Validation Cohort

hospitalized

2270

p-value
582

Not hospitalized

hospitalized

1308

376

p-value

Vaccination history:
Influenza vaccine? Yes (%)

818 (72.5)

311 (27.5)

<0.001

423 (67.6)

203 (32.4)

<0.001

Pneumococcal polysaccharide vaccine? Yes (%)

264 (57.9)

192 (42.1)

<0.001

178 (56.3)

138 (43.7)

<0.001

Pre-testing platelets (median [IQR]) Missing:
67.3%

213.00 [163.00,
267.00]

190.00 [153.25,
241.75]

<0.001

213.00 [171.00,
270.50]

207.00 [156.00,
273.00]

0.266

Pre- testing AST (median [IQR]) Missing: 72.0%

28.00 [21.00, 40.00]

36.00 [25.00, 52.00]

<0.001

25.00 [20.00, 34.50]

31.50 [22.00, 47.00]

<0.001

Pre- testing BUN (median [IQR]) Missing: 67.8%

13.00 [10.00, 19.00]

18.00 [12.00, 30.00]

<0.001

13.00 [10.00, 18.00]

19.00 [12.00, 30.75]

<0.001

Pre- testing Cholride (median [IQR]) Missing:
67.8%

100.00 [98.00, 103.00] 98.00 [95.00, 101.00]

<0.001 101.00 [98.00, 103.00]

99.00 [96.00, 103.00]

0.004

Pre- testing Creatinine (median [IQR]) Missing:
67.7%

0.90 [0.74, 1.11]

1.10 [0.84, 1.57]

<0.001

0.87 [0.71, 1.11]

1.05 [0.79, 1.48]

<0.001

Pre-testing hematocrit (median [IQR]) Missing:
67.4%

40.60 [36.40, 44.12]

40.00 [36.30, 43.80]

0.421

39.35 [36.00, 42.50]

39.00 [34.60, 42.70]

0.285

Pre- testing Potassium (median [IQR]) Missing:
67.2%

4.00 [3.70, 4.20]

4.00 [3.70, 4.40]

0.034

3.90 [3.60, 4.20]

4.00 [3.70, 4.40]

0.005

Immunosuppressive treatment? Yes (%)

162 (67.8)

77 (32.2)

<0.001

69 (63.9)

39 (36.1)

0.001

NSAIDS? Yes (%)

388 (66.2)

198 (33.8)

<0.001

187 (61.1)

119 (38.9)

<0.001

Steroids? Yes (%)

192 (67.1)

94 (32.9)

<0.001

86 (63.7)

49 (36.3)

<0.001

Carvedilol? Yes (%)

38 (50.7)

37 (49.3)

<0.001

17 (53.1)

15 (46.9)

0.002

ACE inhibitor? Yes (%)

160 (62.5)

96 (37.5)

<0.001

83 (62.9)

49 (37.1)

<0.001

ARB? Yes (%)

128 (66.0)

66 (34.0)

<0.001

38 (53.5)

33 (46.5)

<0.001

Melatonin? Yes (%)

51 (60.0)

34 (40.0)

<0.001

24 (48.0)

26 (52.0)

<0.001

Laboratory findings upon presentation:

Home medications:

Social influencers of health:
Population Per Sq Km� (median [IQR])

3.09 [2.68, 3.32]

3.04 [2.67, 3.31]

0.42

3.06 [2.60, 3.32]

3.15 [2.77, 3.38]

<0.001

Median Income ($1000, median [IQR])

57.85 [44.78, 76.40]

55.18 [36.27, 73.09]

<0.001

50.80 [36.06, 65.76]

41.67 [29.38, 64.08]

<0.001

Population Per Housing Unit (median [IQR])

2.29 [1.99, 2.61]

2.15 [1.92, 2.40]

<0.001

2.22 [1.93, 2.46]

2.06 [1.79, 2.31]

<0.001

�

transformed as log10(x+1)

https://doi.org/10.1371/journal.pone.0237419.t001

Prediction modeling results
Imputation methods were evaluated with 1000 repeated bootstrapped samples. We found that
models based on median imputation appeared to outperform those based on data from MICE
imputation, so median imputation was selected for the basis of the final model. Variables that
we examined and were not found to add value beyond those included in our final model for
predicting hospitalization included exposure to COVID 19, other family members with
COVID-19, fever, fatigue, sputum production, flu-like symptoms, recent international travel,
coronary artery disease, heart failure, on immunosuppressive treatment, other heart disease,
other lung disease, pneumovax vaccine, BUN, on angiotensin converting enzyme inhibitor,
angiotensin receptor blocker, toremifene, and paroxetine. Model discrimination was excellent
with an area under the curve of 0.900 (95% confidence interval of 0.886–0.914) in the development cohort, and 0.813 (0.786, 0.839) in the validation cohort. The scaled Brier score was
42.6% (95% CI 37.8%, 47.4%) in the development cohort and 25.6% (19.9%, 31.3%) in the validation cohort. The nomogram is presented in Fig 2, and an online version of the statistical

PLOS ONE | https://doi.org/10.1371/journal.pone.0237419 August 11, 2020

7 / 15

PLOS ONE

Hospitalization risk prediction and outcomes in COVID-19

Fig 1. This figure shows the cumulative incidence of each of the 3 outcomes (going home; transferred to ICU; death) following hospitalization in
our COVID-19 cohort. Values above the days from admission axis indicate numbers of patients at risk.
https://doi.org/10.1371/journal.pone.0237419.g001

model (Fig 3) is available at https://riskcalc.org/COVID19Hospitalization/. The calibration
curves are shown in Fig 4 and suggest that predicted risk matches observed proportions relatively well throughout the risk range. Table 2 shows the sensitivity, specificity, negative predictive value, and positive predictive value at different cutoffs of predicted risk.

Sensitivity analysis
Appropriately managed patients represented the majority of the cohort: 750 patients were hospitalized with a length of stay that exceeded 24 hours (431 in DC and 319 in VC), and 3549
patients were not hospitalized at all (2258 in DC and 1291 in VC). A minority of patients (237
patients, 5.4%) fell in the category of inappropriate initial management: 208 had been initially
sent home from the emergency room but were then admitted within 1 week of emergency
room visit (151 in DC, 57 in VC), and 29 patients were hospitalized but then discharged within
24 hours (12 in DC, and 17 in VC). When tested in each one of those categories, the predictive
model performed very well in the appropriately managed subgroup (area under the curve of
0.821), but its performance was inadequate in the 5.4% of patients who fell in the inappropriate
initial management category.
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Fig 2. A nomogram (graphical version of the model) is shown. Line 1 is used to calculate the points that are associated with each of the predictor variables. Each
subsequent line represents a predictor in the final model. The patient’s characteristic is found on each line, and from it, a vertical line is drawn to find the points that are
associated with each value. All the points are then totaled and located on second to last line. A vertical line is drawn down to the bottom line to locate the predicted risk
of hospitalization produced by the model.
https://doi.org/10.1371/journal.pone.0237419.g002

Discussion
Predictors of hospitalization
Our results confirm a higher risk of hospitalization with older age (median age in hospitalized
patients of 65.5 years compared to 48.0 years in non-hospitalized patients), male sex (56.9% of
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Fig 3. Online risk calculator for risk of hospitalization from COVID-19, found at https://riskcalc.org/COVID19Hospitalization/. The example here is a 55-year-old
white male, former smoker, who presented with cough, shortness of breath, and loss of appetite. He has diabetes and received no vaccinations this year and is only on
NSAIDs for some chronic joint pains. No labs are available yet. His predicted risk of hospitalization is 8.56%. If race is changed to Black, with all other variables
remaining constant, his relative risk almost doubles to an absolute value of 17.22%.
https://doi.org/10.1371/journal.pone.0237419.g003

hospitalized vs 48.3% of non-hospitalized), and medical co-morbidities most prominently
hypertension, diabetes, and immunosuppressive disease (variables significant on univariable
analysis in Table 1, but also relevant in final model). The significant association of shortness of
breath and diarrhea with hospitalization may reflect the need for inpatient supportive care
with these symptoms, regardless of the etiology. Beyond the expected, our results provide
some insights that advance the existing literature:
1. Smoking: The World Health Organization warns of a higher morbidity for COVID-19 in
smokers, and proposes multiple possible mechanisms including frequent touching of face
and mouth during the act of smoking, sharing cigarettes, and underlying lung disease [22].
We found that former smokers rather than current smokers are at higher risk of COVIDrelated hospitalization (Table 1), favoring the underlying lung disease mechanism.
2. Medications: We found a higher risk of hospitalizations in COVID-19 patients who were on
Angiotensin Converting Enzyme (ACE) inhibitors, or angiotensin II type-I receptor blockers (ARBs) on univariable analysis [16,23–24]. However, being on these medications did
not influence the final multivariable model, suggesting that prior associations between
ACEI’s and ARBs with COVID severity may be confounded by the underlying medical comorbidities (hypertension and diabetes) that are linked to highest COVID hospitalization
rates, and which are most often treated with these same drugs. ACE2 can also be increased
by thiazolidinediones and ibuprofen, potentially explaining the higher hospitalization risk
seen in our patients on non-steroidal anti-inflammatory drugs (NSAIDs); in fact, the latest
FDA guidance cautions against the use of NSAIDs in COVID patients [25]. Overall, we recommend caution using retrospective data to draw robust conclusions assigning causation
to drugs vs underlying co-morbidity vs genetically driven ACE2 polymorphism. We
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Fig 4. Calibration curve for the model predicting likelihood of hospitalization. The x-axis displays the predicted probabilities generated by
the statistical model and the y-axis shows the fraction of the patients with COVID-19 who were hospitalized at the given predicted probability.
The 45˚ line, therefore, indicates perfect calibration where, for example, at a predicted probability of 0.2 is associated with an actual observed
proportion of 0.2. The solid black line indicates the model’s relationship with the outcome. The closer the line is to the 45-degree line, the
closer the model’s predicted probability is to the actual proportion. As demonstrated, there is excellent correspondence between the predicted
probability of a positive test and the observed frequency of hospitalization in COVID-19 (+) patients.
https://doi.org/10.1371/journal.pone.0237419.g004

highlight the need for carefully designed, large observational studies or randomized clinical
trials to address these critical questions.
3. Race: African American race was correlated with a higher hospitalization risk (36.2% of
hospitalized vs 21% of non-hospitalized). This is consistent with a recent look at hospitalizations for COVID-19 across 14 states from March 1 to 30 [26]. Race data, which were available for 580 of 1,482 patients, revealed that African Americans accounted for 33 percent of
the hospitalizations, but only 18 percent of the total population surveyed [26]. The authors
proposed explanations like higher rates of medical co-morbidities, higher exposure risks,
and distrust of the medical community as a postulated rationale. Our data, however, show
Table 2. Sensitivity, specificity, positive predictive value, and negative predictive value of the model in the validation dataset at different cutoffs of predicted hospitalization risk.
Sensitivity

Specificity

PPV

NPV

10%

0.769

0.726

0.447

0.916

30%

0.519

0.918

0.646

0.896

50%

0.388

0.963

0.749

0.846

70%

0.253

0.979

0.772

0.820

90%

0.117

0.992

0.800

0.796

https://doi.org/10.1371/journal.pone.0237419.t002
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that the effect of race on the individualized hospitalization risk prediction far outweighs
that of any medical co-morbidity (Fig 2). It is already known that race influences the effectiveness of an immune response [27]. A deeper exploration of the underlying genetics and
biology of race in the defense against and the response to a SARS-CoV-2 infection is
needed. This should be paired with a deeper exploration of social influencers of health such
as population per square kilometer, and population per household which were also relevant
in our nomogram. In our online risk calculator, only the zip code entry is required: the relevant social influencers data are derived from the zip code by our program.

Why do we need a prediction tool?
Given the multitude of risk factors discussed, the nomogram and online risk calculator assist
with obviating challenges of translating complex information to patient-level clinical decisionmaking [28]. During a pandemic, with hospital beds in short supply, it is critical to empower
front-line healthcare providers with tools that can supplement and support decision-making
about who to admit. Advances in tele-health can be leveraged for home monitoring to guide
care delivery in an outpatient setting for those determined to be low risk based on the nomogram calculation. Models like ours developed with data obtained through an automated
abstraction from the electronic health record (EHR) offer the promise of integration within
the EHR to facilitate rapid and efficient implementation into the clinical workflow. Such a
strategy is a pragmatic application of overdue calls for a Learning Health System [29].

How well does this nomogram perform?
Model performance, as measured by the concordance index, is excellent (c-statistic = 0.900).
This level of discrimination is clearly superior to a coin toss or assuming all patients are at
equivalent risk (both c-statistics = 0.5). The calibration of the model is excellent in both the
DC and VC (see Fig 4). The metric that considers calibration, the IPA value, confirms that the
model predicts substantially better than chance or no model at all. Overall, the model performs
very well. Our next step will be to integrate this model into the clinical workflow.

How can this model be integrated in a clinical workflow?
Manually abstracting data and inputting it in an online calculator is cumbersome in a busy
clinical practice. Interpreting the prediction without some frame of reference is complex.
However, failing to see beyond these hurdles risks wasting opportunities to innovate and
improve patient care. It is therefore imperative to develop a clear implementation strategy that
aligns with the existing clinical needs and clinical operations of a health organization. One
could start by identifying the clinical problems that would benefit from this prediction tool,
and reference the information in Table xx on sensitivity, specificity, positive predictive value,
and negative predictive value at different prediction cutoffs to provide a framework for clinical
application. An illustrative example now being explored from our own health system is the use
of this calculator to tailor the intensity of home monitoring for COVID positive patients. Currently, every patient who tests positive for COVID is being called daily for 14 days to check on
their symptoms and identify disease progression early enough for intervention. With only 20–
30% of COVID positive patients progressing to the point of requiring hospitalization, the
nurses can use our prediction tool to identify this high risk group and only call them daily,
while reducing the intensity of follow-up with the rest.
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Limitations
This is not a multicenter study. It is important to note though that it includes all hospitals and
outpatient facilities of the Cleveland Clinic Health System within the US (>220 outpatient locations and18 hospitals in Ohio and Florida) creating robust sampling of the COVID-19 population. As with any other statistical model, other hospital systems may elect to validate this model
internally for their specific patient populations as they contemplate options for integrating it in
their workflow. Given the alternative of no or constantly changing practice guidelines, implementation of this nomogram into our clinical workflow will allow prospective evaluation of its
impact on patient care and outcomes. Our model includes age as a predictor: this may mitigate
our ability to identify risk factors for disease progression specific in the younger population,
and may underestimate the risks in the younger population with less severe disease and less
likely to seek medical care. Lastly, although our model performs very well in the majority of
COVID positive patients, more research is needed to optimize it for the sub group (5.4% of the
total cohort in our series) with either delayed or unnecessary admission.

Conclusions
Drivers of disease progression and worsening in COVID-19 are multiple and complex. We
developed a statistical model with excellent predictive performance (c-statistic of 0.926) to
individualize the hospitalization risk assessment at the patient level. This could help guide clinical decision-making and resource allocation.
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